Quick Facts
| CAS Number | 22189-32-8 |
|---|---|
| Molecular Formula | C14H24N2O7 · 2HCl · 5H2O |
| Molecular Weight | 495.35 |
| Pharmacopoeia | USP/IN HOUSE/EP |
| Packaging | 25 KG/DRUM |
Product Overview
Spectinomycin Hydrochloride (Pharma Grade) is an aminoglycoside antibiotic produced by Streptomyces spectabilis, first discovered by Mason et al. in 1961. It demonstrates high antibacterial activity against Neisseria gonorrhoeae (including β-lactamase producing strains) and moderate activity against many Enterobacteriaceae species. It also shows good activity against Ureaplasma urealyticum.
In human medicine, Spectinomycin HCl serves as an important alternative therapy for penicillin-allergic patients. It is primarily indicated for the treatment of gonococcal infections and is also used in combination therapy for pelvic inflammatory disease. Its oral absorption is superior to other aminoglycosides such as neomycin sulphate, kanamycin sulphate, and gentamicin sulphate. It is also the safest aminoglycoside for injectable administration.
Quality Specifications
| Purity | As per USP/EP monograph |
|---|---|
| Residual Solvents | Compliant with ICH Q3C |
| Heavy Metals | Compliant with pharmacopoeia limits |
| GMP Status | Manufactured under GMP conditions |
Pharmaceutical Applications
Gonorrhea Treatment
First-line intramuscular therapy for uncomplicated gonococcal infections, particularly in penicillin-allergic patients and β-lactamase-producing strains.
Pelvic Inflammatory Disease
Used in combination regimens for pelvic inflammatory disease (PID) as an alternative to cephalosporin-based therapy.
Therapeutic Indications
- Gonorrhea: Urogenital, anorectal, and pharyngeal gonococcal infections
- Pelvic Inflammatory Disease: Combination therapy for PID
- Ureaplasma Infections: Ureaplasma urealyticum infections
- Penicillin Allergy: Alternative therapy for β-lactam allergic patients